4//SEC Filing
Donovan Joanne M. 4
Accession 0001562180-25-000697
CIK 0001710072other
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 4:05 PM ET
Size
11.5 KB
Accession
0001562180-25-000697
Insider Transaction Report
Form 4
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-01-28−25,000→ 175,000 totalExercise: $7.08Exp: 2033-08-17→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2025-01-28$7.08/sh+25,000$177,000→ 41,358 total - Sale
Common Stock
2025-01-28$27.63/sh−25,000$690,658→ 16,358 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
- [F2]Includes 1,820 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $27.09 to $27.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001644087
Filing Metadata
- Form type
- 4
- Filed
- Jan 29, 7:00 PM ET
- Accepted
- Jan 30, 4:05 PM ET
- Size
- 11.5 KB